BR0113312A - Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes - Google Patents

Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes

Info

Publication number
BR0113312A
BR0113312A BR0113312-8A BR0113312A BR0113312A BR 0113312 A BR0113312 A BR 0113312A BR 0113312 A BR0113312 A BR 0113312A BR 0113312 A BR0113312 A BR 0113312A
Authority
BR
Brazil
Prior art keywords
compounds
type
composition
tetrazole
diabetes
Prior art date
Application number
BR0113312-8A
Other languages
English (en)
Portuguese (pt)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0113312A publication Critical patent/BR0113312A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0113312-8A 2000-08-15 2001-08-09 Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes BR0113312A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22549400P 2000-08-15 2000-08-15
PCT/EP2001/009207 WO2002014312A1 (en) 2000-08-15 2001-08-09 Tetrazolyl-phenyl acetamide glucokinase activators

Publications (1)

Publication Number Publication Date
BR0113312A true BR0113312A (pt) 2003-07-01

Family

ID=22845106

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113312-8A BR0113312A (pt) 2000-08-15 2001-08-09 Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes

Country Status (20)

Country Link
US (3) US6369232B1 (enExample)
EP (1) EP1311504B1 (enExample)
JP (1) JP3961948B2 (enExample)
KR (1) KR100518061B1 (enExample)
CN (1) CN1209362C (enExample)
AR (1) AR031718A1 (enExample)
AT (1) ATE297921T1 (enExample)
AU (2) AU8399801A (enExample)
BR (1) BR0113312A (enExample)
CA (1) CA2419416C (enExample)
DE (1) DE60111540T2 (enExample)
DK (1) DK1311504T3 (enExample)
ES (1) ES2243541T3 (enExample)
MX (1) MXPA03001275A (enExample)
PA (1) PA8525201A1 (enExample)
PE (1) PE20020386A1 (enExample)
PT (1) PT1311504E (enExample)
UY (1) UY26885A1 (enExample)
WO (1) WO2002014312A1 (enExample)
ZA (1) ZA200300904B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
NZ539013A (en) 2002-10-03 2007-05-31 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
EP1594863A1 (en) * 2003-02-11 2005-11-16 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
KR20070006816A (ko) 2004-04-02 2007-01-11 노파르티스 아게 티아졸로피리딘 유도체, 이를 함유하는 제약 조성물 및글루코키나제 매개형 증상의 치료 방법
KR100830007B1 (ko) 2004-04-02 2008-05-15 노파르티스 아게 2형 당뇨병 치료에 유용한 글루코키나제 활성화제로서의술폰아미드-티아졸피리딘 유도체
NZ564608A (en) 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
CN101218237B (zh) * 2005-07-11 2012-03-28 田边三菱制药株式会社 肟衍生物及其制备方法
EP1921074A1 (en) 2005-08-31 2008-05-14 Astellas Pharma Inc. Thiazole derivative
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
BRPI0618062A2 (pt) * 2005-11-03 2011-08-16 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
ES2381864T3 (es) * 2005-12-15 2012-06-01 Nihon Nohyaku Co., Ltd. Derivado de ftalamida, pesticida agrícola u hortícola y utilización del pesticida
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
ATE522518T1 (de) 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
US7910747B2 (en) * 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
US8314247B2 (en) * 2007-01-10 2012-11-20 Mitsubishi Tanabe Pharma Corporation Hydrazone derivative
KR20090121376A (ko) 2007-03-07 2009-11-25 교린 세이야꾸 가부시키 가이샤 글루코키나아제 활성화 물질
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
AU2008310519B2 (en) * 2007-10-08 2013-05-02 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
EP2236498A4 (en) * 2008-01-18 2012-02-22 Astellas Pharma Inc PHENYLACETAMIDE DERIVATIVE
CA2722733C (en) * 2008-04-28 2016-02-23 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776917A (en) * 1972-06-05 1973-12-04 Schering Corp 2-amino-6-phenalkyl-aminopyridines and derivatives thereof
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5461049A (en) * 1994-05-27 1995-10-24 Warner-Lambert Company Amide tetrazole ACAT inhibitors
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
PL334833A1 (en) * 1997-01-28 2000-03-27 Merck & Co Inc Thiazolobenzenosulphonamides as beta3 agonists for treating diabetes and obesity
BR0009486B1 (pt) * 1999-03-29 2011-03-09 composto que compreende uma amida, composição farmacêutica que compreende esse composto, seu uso e processo para a preparação do mesmo.

Also Published As

Publication number Publication date
CA2419416C (en) 2009-10-13
UY26885A1 (es) 2002-02-28
WO2002014312A1 (en) 2002-02-21
US20020065275A1 (en) 2002-05-30
US20020035266A1 (en) 2002-03-21
KR100518061B1 (ko) 2005-09-28
AU8399801A (en) 2002-02-25
ES2243541T3 (es) 2005-12-01
EP1311504A1 (en) 2003-05-21
EP1311504B1 (en) 2005-06-15
CA2419416A1 (en) 2002-02-21
MXPA03001275A (es) 2003-06-30
US6388088B1 (en) 2002-05-14
US20020035267A1 (en) 2002-03-21
PE20020386A1 (es) 2002-05-13
ATE297921T1 (de) 2005-07-15
JP2004506632A (ja) 2004-03-04
ZA200300904B (en) 2004-04-30
CN1209362C (zh) 2005-07-06
DE60111540T2 (de) 2006-03-16
DE60111540D1 (de) 2005-07-21
JP3961948B2 (ja) 2007-08-22
PA8525201A1 (es) 2002-07-30
PT1311504E (pt) 2005-10-31
AU2001283998B2 (en) 2005-10-20
AR031718A1 (es) 2003-10-01
US6441180B1 (en) 2002-08-27
DK1311504T3 (da) 2005-10-17
KR20030022408A (ko) 2003-03-15
US6369232B1 (en) 2002-04-09
CN1466584A (zh) 2004-01-07

Similar Documents

Publication Publication Date Title
BR0113312A (pt) Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes
BR0110492A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto
BR0317268A (pt) Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos
BRPI0212775B8 (pt) composto de 1,2,4-triazol e medicamento
BR0114708A (pt) Compostos, composições farmacêuticas que compreendem os mesmos, utilização dos compostos, processo de tratamento de distúrbios e de obesidade, e processos para a preparação dos compostos e de uma composição
NO20033385D0 (no) Fuserte heterocykliske forbindelser
ATE381542T1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
PE20061357A1 (es) COMPUESTOS DERIVADOS DE AMINOSULFONILO COMO INHIBIDORES DE LA 11-ß-HSD-1
WO2000063208B1 (en) Substituted imidazoles, their preparation and use
BR0110704A (pt) Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase
BR0110573A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto
BR0009320A (pt) Dibenzopiranos como antagonistas do receptor glicocorticóide para o tratamento da diabete
BR0309964A (pt) Derivados anticonvulsivos de sulfamoto substituìdo
CO5690638A2 (es) Nuevos compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos; proceso para su preparacion y composiciones farmaceuticas que los contienen
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
PL1716152T3 (pl) Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych
ATE556067T1 (de) Modulatoren des vanilloid rezeptors
UY28528A1 (es) Nuevos compuestos
ATE457971T1 (de) Derivate von 4-hydroxybutansäure und deren höheren homologen als liganden von g- hydroxybutyrat- (gbh-)rezeptoren, pharmazeutische zusammensetzungen, die diese enthalten, und pharmazeutische anwendungen
BR0313377A (pt) Bifenilcarnboxamidas substituìdas por n-aril piperidina como inibidores de secreção de apolipoproteìna b
DE60221348D1 (de) Substituierte chinoline zur behandlung von durch protozoen und retroviren verursachten co-infektionen
MXPA05013772A (es) 4-(aminometil)-piperidin benzamidas como antagonistas de 5ht4.
WO2006126939A8 (en) Novel 8-sulfonylamino-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor
MX2007008308A (es) Derivados de n-(heteroaril)-1h-indol-2-carboxamidas y su utilizacion como ligandos del receptor vaniloide trpv1-.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2125 DE 27/09/2011.